Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential

RICHMOND, Va., July 5, 2012 /PRNewswire/ -- Health Diagnostic Laboratory, Inc. (HDL, Inc.) is bringing its innovative approach to identifying and managing risk for chronic disease to the Nation's Capital for the inaugural Population Health Innovations Showcase, Wednesday, July 11, 2012, on Capitol Hill. Care Continuum Alliance (CCA), the leading voice in population health, is hosting the Showcase to provide a forum for population health and chronic disease management innovators to share expertise, technology, and strategies with lawmakers, regulatory and government officials, and others who work on expanding access to wellness, prevention and care management.

"Health Diagnostic Laboratory looks forward to our participation in the Population Health Innovations Showcase and to educating leaders in government about life saving technologies that provide positive outcomes on the health care system," said Anna McKean, Executive VP of Strategic Initiatives at HDL, Inc.

"Currently, the incidence of chronic disease continues to accelerate despite widespread laboratory testing. Health Diagnostic Laboratory was founded on the premise that many widely used laboratory tests do not adequately identify the risk for specific chronic diseases, and therefore limit the opportunity for prevention," said Mckean.

The Centers for Disease Control reports that 75% of overall medical costs are driven by preventable chronic conditions like cardiovascular disease (CVD) and diabetes. Health risk, however, are not identified until after disease reaches a chronic state. Health Diagnostic Laboratory, Inc. will attend the inaugural Population Health Innovations Showcase with a mission to help change the paradigm and to identify disease risk earlier so that the conditions can be treated and even reversed. 

HDL, Inc., a fully CAP/CLIA accredited clinical laboratory, is surpassing the traditional lipid blood test by offering an innovative biomarker panel of laboratory blood tests. By testing for inflammation, oxidative and myocardial stress, metabolic function, along with lipoprotein particles and pharmacogenetic markers, medical professionals can tailor the most effective treatment based on an expanded, comprehensive patient profile.  The result -- earlier detection of risk factors, more advanced evidence-based treatments, and fewer patients progressing to overt cardiovascular disease and diabetes. 

The HDL, Inc. approach emphasizes prevention of disease by utilizing evidence-based practice guidelines and patient empowerment strategies.  Evidence-based and actionable biomarkers in blood testing are available and affordable to practicing clinicians, patients, as well as employer groups. These innovative tests coupled with patient-engagement strategies hold enormous promise for reversing the rising global trends in cardiovascular disease and diabetes.   This approach to healthcare results in improved clinical knowledge and improved quality in patient care, which ultimately creates significant reduction in healthcare costs.

For more information
Population Health Innovations Showcase
http://www.carecontinuum.org/innovations_showcase.asp

About Health Diagnostic Laboratory, Inc.
Health Diagnostic Laboratory, Inc. (HDL, Inc.), a CAP accredited leader in health management, offers a comprehensive test menu of risk factors and biomarkers for cardiovascular and related diseases. Our systematic approach identifies factors contributing to disease and provides a basis for effective treatment, allowing physicians to more effectively manage patients. As an added value, patients receive a personalized overview of their risk factors along with intensive counseling from expert Health Coaches at no additional cost, improving compliance and enhancing satisfaction. For more information about HDL, please visit www.hdlabinc.com.

SOURCE HDL, Inc.